Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Up 1,266.7% in January

Defence Therapeutics Inc. (OTCMKTS:DTCFF) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 4,100 shares, a growth of 1,266.7% from the January 15th total of 300 shares. Based on an average daily trading volume, of 64,900 shares, the days-to-cover ratio is presently 0.1 days.

Defence Therapeutics Trading Up 3.2 %

Shares of Defence Therapeutics stock opened at $0.80 on Thursday. Defence Therapeutics has a one year low of $0.27 and a one year high of $1.45. The stock has a 50 day moving average price of $0.50 and a 200-day moving average price of $0.47.

Defence Therapeutics Company Profile

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.